Clinical adoption intelligence · UK & Europe

Regulatory approval
is a milestone.
Adoption is the destination.

The device works. The evidence is solid. What gets it to patients is understanding every human in the system — and building the conditions for each of them to move.

Start a conversation The root cause →
A bird emerging from its shell
The launch happened.

Stocking orders, training, investment committed. Now the device needs to reach the patients it was built for.

Reference sites are great.

But usage sites are different. Success at one does not automatically become success at the other.

The repeatable model.

Understand how a workhorse hospital really operates and that knowledge travels. That is when adoption becomes a business.

The gap The model Framework The cost Insights Services About FAQ The Book ↗ Talk to us →

The root cause

Adoption doesn’t fail
because the device is wrong.

It fails because of what happens between what a company believes about its product and what a customer actually needs to hear. Three layers. Rarely in dialogue. Almost always the source of the problem.

Layer 01

What the company believes

The clinical evidence is strong. The device works. The strategy is built. The brief has been given to the field.

→

Layer 02

What the rep communicates

Generic messaging. Approved materials. A training day from six months ago. A question they can’t answer in the room.

→

Layer 03

What the customer actually needs

A specific answer to a specific clinical question. In this conversation. Right now. From someone who understands how this environment operates.

This is a behaviour gap, not an information gap. The information exists. The system to deliver it — in the room, at the right moment, to the right person — almost never does. Lumenara bridges that gap.

How the work gets done

Four phases.
One outcome.

A repeatable engagement model built from 17 years of what actually works inside medical device commercialisation. Each phase has a defined output. Nothing moves forward until the output is real.

Phase 01

Diagnostic

Understand the specific adoption barrier. Clinical, commercial, or structural. We don’t start with recommendations until we know what’s actually blocking — because activity without diagnosis accelerates whatever is already happening, including the failure.

Phase 02

Stakeholder Map

The full human experience

Map every decision-maker and influencer in the buying pathway. What they protect. What they need to hear. Where the current strategy is missing. The commercial message that resonates with one stakeholder actively alienates another. The strategy must be built multi-stakeholder from the start, not added later.

Observer Flow applied here

Phase 03

Strategy Build

Clinical adoption pathway. Commercial messaging matrix. Market access approach. Built for the specific product, trust type, and buying cycle. Not repurposed from another launch. Not generic advisory output. Specific to this device and this system.

Phase 04

Implementation

Working directly with the commercial team until the approach is operational. Not a handover document. A working engagement. We are in the field conversation, the board room, and the procurement meeting until adoption moves.

Each engagement is structured around a specific commercial question. We don’t run general advisory retainers. We solve defined problems.

The Observer Flow Framework

The missing key to
unlocking performance.

Commercial strategy is planned at a sophisticated level. The product works. The evidence is solid. The stakeholder map is built. Then a conversation goes wrong, a decision is made from pressure rather than clarity, or a leader’s identity gets tangled with an outcome. The Observer Flow Framework addresses what almost no business framework touches: the internal operating system of the person running the strategy.

This framework did not come from management theory. It emerged from lived experience — the full account is in UbU by Arun Kumar. It was then verified independently against Vedic psychology and contemporary neuroscience. That origin is precisely why it works where other frameworks do not: it was tested on a human being under real pressure before it was applied to a commercial conversation.

In MedTech adoption, the barrier is almost never the product. It is the quality of the decisions made by the people building the adoption programme — under pressure, with incomplete information, and with identity attached to outcomes. Observer Flow gives commercial leaders a repeatable internal practice for catching reactive patterns before they become commercial decisions. Psychology inside compliance.

What it looks like in the room

The moment — Mr Holloway, consultant breast surgeon

“My re-excision rate is already below the national average. I’m not sure what this adds to my practice.”

Observe → Surgeon is citing his own performance metric. This is not a clinical objection. It is identity protection. He has built professional pride around this number.

Name it → Barrier: workflow and identity protection. He is not sceptical of the device. He is sceptical of disruption to something that already works.

Reorientate → Do not defend the device. Acknowledge his performance. Then shift the conversation to his team — specifically his registrars.

The redirect — what the rep says next

“That’s a strong result — genuinely. I’m curious about one thing: what happens to that number when your registrars are leading the list without you in the room?”

What happened: Rep used Observer Flow redirect. Surgeon engaged. Conversation moved from defence to genuine clinical interest.

Time in call: 4 minutes · 73% continuation rate in comparable accounts

Surgeon’s next question: “What about re-excision cases specifically — second operations where initial margins weren’t clear. Can it be used there? My registrars do a lot of those.”

The four steps — Not a process you run. A reflex you train.

Step 1 — Observe

Catch it before it becomes a decision

The pause between stimulus and response is where commercial judgement lives. You are not the pressure. You are the one noticing it.

Step 2 — Name it

Which pattern is running?

Identity protection. Fear of the board conversation. The need for approval from the clinical champion. What you cannot name owns your strategy.

Step 3 — Thank it

Complete the arc, don’t suppress it

Acknowledge what the feeling was trying to do. Suppression keeps it in the room. Completion frees the decision from it.

Step 4 — Return

Return to the mission

Not back to the noise or the pressure. Back to why the work matters. The business mission as compass — the orientation that holds when everything else is pulling.

Where it changes business outcomes

High-stakes decisions

Clarity under pressure

Board presentations, adoption pivots, distributor negotiations. The decisions that define programmes happen when pressure is highest. Observer Flow trains the pause that separates a reactive call from a clear one.

Commercial team performance

The gap between capability and output

The gap between what a commercial team can do and what it actually does is almost always internal. Reactive patterns, identity attached to targets, fear of clinical pushback. The framework addresses the operating system, not just the skill set.

Leadership identity

The leader who stays in the observer state

Post-launch stalls, restructures, and adoption plateaus test every leader managing them. The leader who can observe rather than react under that pressure makes better calls, holds teams together, and recovers faster.

Talk to Arun Kumar → Explore the full framework →

The cost of your strategy

Most MedTech companies know
something isn’t working.

Most don’t know what it’s costing them, or why. Select the scenario closest to where you are. We’ll show you what it typically costs and what needs to happen first.

Patterns that repeat

Built from inside
the launches and the stalls.

These are the patterns that repeat. Across therapy areas, commercial models, and market stages. Not theory — lived experience from inside the launches, the stalls, and the recoveries.

From barriers to flow

Adoption sequencing · Reference vs usage

The 12-Month Gap: Why Yes Is Not Adoption

The distance between a surgeon saying yes in principle and consistent theatre use runs 12 to 24 months. Commercial forecasts that ignore this sequence consistently underperform. Planning the sequence before starting the clock is what separates launches from stalls.

Adoption sequencing · Reference site strategyRead on LinkedIn →
Every stakeholder faces a different barrier

Stakeholder strategy · System selling

Six People. Six Different Conversations.

Every hospital has a procurement lead, a devices committee, a clinical governance sign-off, and a budget holder whose cycle does not align with the launch timeline. The commercial message that resonates with one stakeholder actively alienates another. The strategy must be multi-stakeholder from the start.

Stakeholder mapping · System selling in healthcareRead on LinkedIn →
The architecture of clinical adoption

Adoption recovery · Post-launch diagnostic

Post-Launch Stall: Diagnosis Before Activity

Activity without diagnosis does not fix an adoption problem. Post-launch stalls have a small number of root causes — wrong site type, wrong stakeholder, wrong message — each requiring a completely different response. The instinct to increase activity is almost always wrong.

Post-launch recovery · Root cause diagnosticFollow on LinkedIn →

These insights form the foundation of how Lumenara approaches every engagement — built from 17 years operating inside MedTech launches across therapy areas, commercial models, and markets.

What we do

Specific problems.
Specific engagements.

Each engagement is structured around a defined commercial question. Not general advisory retainers. Specific problems with a clear diagnostic, a built strategy, and a working implementation.

Clinical Adoption Strategy

Stakeholder mapping, reference and usage site strategy, workflow integration, training architecture, health economic evidence calibrated to audience.

  • Reference vs usage site distinction — built explicitly
  • Stakeholder map: what each buyer protects, what they need to hear
  • Commercial messaging matrix by stakeholder
  • NHS procurement and ICS engagement

The sequence that works: Secure KOL commitment with clinical trial architecture. Use that name to unlock secondary academic centres. Only then approach workhorse hospitals with the commercial model built in real time. Timeline: 18 months from KOL engagement to first scalable usage site. Second site: 40% faster.

Early Market Architecture

Phase 1 sequencing, site prioritisation, investor narrative, UKCA and EU MDR commercial strategy, AHSN adoption pathways.

  • Pre-launch adoption architecture — reference and usage from day one
  • KOL identification and commitment strategy
  • Early market sequencing and site prioritisation
  • Investor commercial narrative built on realistic adoption timelines

Commercial & Clinical Advisory

Ongoing partnership combining senior commercial experience with active clinical practice intelligence. For companies that need the clinical environment understood from the inside.

  • Board-level commercial diagnosis and recovery planning
  • Distributor network development and management
  • European market entry strategy
  • KOL development and centre of excellence design

Adoption Recovery

For launches that have stalled. Root cause diagnostic before any new activity. A rebuilt pathway to scale based on what the system actually requires — not what the launch plan assumed.

  • Root cause diagnostic — reference vs usage site distinction
  • Stakeholder barrier reassessment
  • Economic case rebuild for procurement audience
  • Re-sequenced adoption programme for usage sites

The next layer

The conversation in the room
is where adoption advances
or stalls.

The Observer Flow Framework addresses the internal operating system of the commercial leader. The next problem is the conversation they are having in the room — and the intelligence that should be available to them in real time: what this specific customer has published, how they operate, what the pattern of resistance looks like in comparable accounts, and exactly what approved redirect matches this barrier type and this person.

Every prompt pre-approved by medical affairs and compliance. Not a coaching tool. A governed, auditable, repeatable framework for reading the human in the room — and knowing precisely what to do next. Psychology inside compliance.

We are building this. It does not yet exist in this market. If you want to be part of the architecture before it launches, get in touch.

Get in touch →
Arun Kumar

Founder

Arun Kumar

17 years of commercial leadership in medical devices across UK and European markets — sports medicine, hernia, gynaecology, neuromodulation, and cardiac implants. Director-level experience across direct sales and distributor models, from early market entry through to post-launch scale.

The specific insight that drives Lumenara: most commercial strategies for MedTech are built by people who understand either the clinical environment or the commercial one. Rarely both. The gap between them is where products stall.

Common questions

What people ask
at the start.

Honest answers to the questions we hear before almost every engagement.

A reference site is a prestigious academic centre that provides clinical credibility and endorsement. A usage site is a high-volume workhorse hospital where the device must function as part of routine practice at scale. Reference sites value innovation and clinical conversation. Usage sites value workflow fit, training simplicity, and a clear economic case. The commercial message that works at one actively alienates the other. Confusing the two is one of the most common reasons MedTech launches stall after strong initial reference site performance.
Because they require completely different engagement strategies. A reference site adopts because of clinical interest. A usage site adopts because the device fits the workflow, the training burden is manageable, and the economic case is compelling for that specific audience. The model that works at an academic centre — clinical innovation language, KOL advocacy, outcome data — does not transfer. Companies that apply the reference site playbook to usage sites consistently find the model fails to replicate.
The Observer Flow Framework is a four-step practice — Observe, Name It, Thank It, Return — developed by Arun Kumar from lived experience and verified against Vedic philosophy and contemporary neuroscience. In a business context, it addresses the internal operating system of the person running the commercial strategy. Most commercial frameworks focus on external factors: the market, the stakeholder, the process. Observer Flow addresses what they miss: the reactive patterns, identity attachment, and pressure responses of the leader making the decisions. It is not a mindfulness tool. It is a performance tool. The full framework is explored in depth in the book UbU at ubuobserver.com.
Three things happen. The board conversation shifts from explaining underperformance to presenting a clear adoption pipeline. The workhorse hospital becomes a commercial proof point — evidence the model works at scale, not just at the academic centre. And adoption compounds: each new site moves faster than the last because the understanding of how that type of hospital operates transfers. The second usage site adoption runs approximately 40% faster than the first when the model is built correctly.
Typically 18–36 months from first usage site engagement to a model that genuinely replicates. This reflects the patience required to understand how a workhorse hospital actually operates — its procurement cycle, theatre scheduling, training capacity, and economic decision-making. Companies that try to accelerate by applying a reference site playbook to usage sites consistently find the model does not transfer. The sequence cannot be skipped. It can only be built correctly or paid for later.
Yes. We work across UK and European markets, with specific experience in Germany, France, the Netherlands, and Ireland. We also work with US and global device companies navigating EU MDR compliance and UK market entry. The NHS has a distinct procurement architecture and value framework that does not translate directly from fee-for-service markets. Understanding that distinction before entering is significantly less expensive than learning it after.

Perspectives from the field

Most MedTech doesn't fail because the product is wrong. It fails because the company tries to scale from the middle. Reference sites and usage sites require completely different strategies — and most companies apply the same approach to both. The correct sequence takes 18 months. The second site adopts 40% faster because by then the operating model exists. Read on LinkedIn →
The gap between a clinician saying yes and that device becoming part of regular practice runs 12 to 24 months — not because they changed their mind, but because nobody mapped what had to happen in between. Yes is not adoption. Yes is the beginning of a process that nobody fully owns. Read on LinkedIn →
The surgeon wanted it. The evidence was strong. It still didn't move. Healthcare systems are designed to slow down the introduction of new things — that's not dysfunction, that's the system working as intended. Mapping the clinical champion is table stakes. The companies that achieve adoption also map everyone who can say no — before the product is in the building. Read on LinkedIn →
Getting a leading academic centre to use your device is not the same as building a commercial position. The reference site validates the device. The workhorse hospital — the district general doing 400 procedures a year — is where the business is built. Reference sites give you permission to have the conversation. Usage sites are the conversation. Read on LinkedIn →
Enthusiasm is not commitment. A surgeon intellectually engaged with your device is not the same as one who will change their practice and bring colleagues along. The early adopter who builds your market has a specific profile — not just curious, but motivated to be first, with institutional credibility. Finding that person takes longer. It's the only investment that compounds. Read on LinkedIn →
The conversation that needs to happen is: here is the adoption sequence, here is what each step requires, here is a realistic timeline. That conversation is uncomfortable. It is less expensive than twelve months of under-delivery followed by a restructure. The companies that scale don't have faster health systems — they have better maps. Read on LinkedIn →
Most health economic models are built to impress the person who commissioned them — not the person who approves the budget. The finance director wants to know what this costs in year one, what it saves in year two, and whether that saving lands in their budget or someone else's. Evidence without the right framing for the right audience is just a document. Read on LinkedIn →
Every NHS trust has a different procurement structure, budget cycle, and clinical politics. The surgeon who championed it in hospital one has no influence in hospital two. What you've built in the first account is a proof of concept. The companies that scale well treat their first successful sites as learning investments — extracting the method, not just the outcome. Read on LinkedIn →
Your device is one of fifteen a distributor represents. It is new, requiring more work to sell and competing for attention with products that already generate commission. Managing a distributor relationship is an active commercial function — not a passive one. The companies that succeed treat distributors as a channel to manage, not a team to trust. Read on LinkedIn →
Activity without diagnosis doesn't fix an adoption problem — it accelerates whatever is already happening, including the failure. Post-launch stalls have a small number of root causes, each requiring a different response. Recovery is possible. It starts with the right question, not more of the same activity. Read on LinkedIn →

Start the conversation

If you want the numbers
to follow the investment —
let’s talk.

Not a discovery call that ends in a proposal. A real conversation about where you are, what kind of sites you are working with, and whether we are the right fit.

Tell us the situation. We will tell you what we see — including if what you need is not us.

arun@lumenara.co.uk
+44 (0)7763 911 139
lumenara.co.uk
UbU — Untitled By Unknown by Arun Kumar

The book behind the framework

UbU — Untitled By Unknown

The Observer Flow Framework emerged from lived experience, not theory. UbU traces the journey through professional identity collapse and the discovery of the framework — verified against Vedic philosophy, Jungian psychology, and contemporary neuroscience. Published by Lumenara Press, 17 August 2026.

Read the book → ubuobserver.com